Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for its prioritize ...
First subjects enrolled in the KL1333 study
Successful rights issue
Broadened project portfolio
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 (14,271,000).Earnings per s ...
Capital raising characterizes NeuroVive ́s first quarter
Successful rights issue and final patient treated in phase III study on CicloMulsion®
The listing on Nasdaq OMX creates possibilities for the future